Announcement from the Specialty Board:

A meta-analysis of prospective, randomized trials comparing the treatment of sepsis with (-lactam monotherapy or with a (-lactam and aminoglycoside combination regimen failed to demonstrate a significant benefit for combination therapy (8) (Class II). Of the 7,586 patients evaluated, 1,200 had sepsis from VAP or hospital-associated pneumonia (HAP). ................
................